Cartography creates a single‑cell‑resolution antigen atlas that maps protein expression across millions of cells from thousands of tumor samples, identifying tumor‑selective antigens and assessing their presence on normal tissues. By integrating genomics, proteomics, and binder discovery, the platform provides safety and efficacy data that guide the design of immunotherapies such as T‑cell engagers, CAR‑T cells, and antibody‑drug conjugates, helping pharma and biotech companies accelerate target discovery and de‑risk development.
Funding
$63M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer immunotherapies are constrained by a shortage of highly specific, safe targets, leading to limited efficacy and off‑target toxicities for many patients.
Solution
Cartography builds a comprehensive, single‑cell–resolution antigen atlas that maps protein expression across millions of cells from thousands of patient tumor samples. By integrating single‑cell genomics, proteomics, and novel binder discovery methods, the platform identifies tumor‑selective antigens and evaluates their presence on normal tissues, enabling precise safety and efficacy assessments. This data‑driven view of antigen expression replaces reliance on histology or genetic mutations, guiding the design of immunotherapies—such as T‑cell engagers, CAR‑T cells, and antibody‑drug conjugates—that are both broadly applicable across a patient’s tumor and highly specific to cancer cells. The resulting target profiles accelerate discovery, de‑risk development, and expand the range of cancers amenable to immunotherapy.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing immuno‑oncology therapeutics, as well as research institutions seeking validated, tumor‑selective antigen targets.
Features
- Single‑cell genomics and proteomics pipelines profiling millions of cells from diverse tumor cohorts
- Novel binder discovery platform to generate high‑affinity reagents against identified antigens
- Comprehensive antigen atlas that quantifies expression on tumor versus normal tissues for safety profiling
- Computational tools that prioritize targets based on tumor coverage, specificity, and druggability across multiple therapeutic modalities
- Integrated data export and API support for seamless incorporation into pharmaceutical discovery workflows